Allele Loss and Down-Regulation of Heparanase Gene Are Associated with the Progression and Poor Prognosis of Hepatocellular Carcinoma

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Huang, Guo Liang ^a,b   Li, Bin Kui ^a   Zhang, Mei Yin ^a   Wei, Rong Rong ^a   Yuan, Yun Fei ^a   Shi, Ming ^a   Chen, Xiao Qian ^a   Huang, Long ^a   Zhang, Hui Zhong ^a   Liu, Wanqing ^c   Huang, Bi Jun ^a   Li, Honghua ^d   Zheng, Xiao Feng ^d   Luo, Xian Rong ^e   Wang, Hui Yun ^a,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CHICAGO   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e No 458 Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPARANASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; MESSENGER RNA;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 4Q; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOSS; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHROMOSOMES, HUMAN, PAIR 4; DISEASE PROGRESSION; DNA, VIRAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GLUCURONIDASE; HEPATITIS B VIRUS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR BURDEN; YOUNG ADULT;

HEPATITIS B VIRUS;

EID: 84865651820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044061     Document Type: Article

References (36)

1. Dempsey LA, Brunn GJ, Platt JL, (2000) Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 25: 349-351.
2. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, et al. (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68: 729-777.
3. Ilan N, Elkin M, Vlodavsky I, (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38: 2018-2039.
4. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, et al. (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66: 1455-1463.
5. Ben-Zaken O, Gingis-Velitski S, Vlodavsky I, Ilan N, (2007) Heparanase induces Akt phosphorylation via a lipid raft receptor. Biochem Biophys Res Commun 361: 829-834.
6. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, Ilan N, (2008) Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 68: 10077-10085.
7. Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, et al. (2001) Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 61: 4655-4659.
8. Esti C, Ilana D, Inna N, Ofer B-I, Ran K, et al. (2008) Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer 113: 1004-1011.
9. Ohkawa T, Naomoto Y, Takaoka M, Nobuhisa T, Noma K, et al. (2004) Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation. Lab Invest 84: 1289-1304.
10. Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, et al. (2003) Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 83: 613-622.
11. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, et al. (2006) Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 8: 1055-1061.
12. Dong S, Wu XZ, (2010) Heparanase and hepatocellular carcinoma: promoter or inhibitor? World J Gastroenterol 16: 306-311.
13. Li SP, Wang HY, Li JQ, Zhang CQ, Feng QS, et al. (2001) Genome-wide analyses on loss of heterozygosity in hepatocellular carcinoma in Southern China. J Hepatol 34: 840-849.
14. Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, et al. (1999) Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 25: 284-289.
15. Nishimura T, Nishida N, Komeda T, Fukuda Y, Ikai I, et al. (2006) Genome-wide semiquantitative microsatellite analysis of human hepatocellular carcinoma: discrete mapping of smallest region of overlap of recurrent chromosomal gains and losses. Cancer Genet Cytogenet 167: 57-65.
16. Huang SF, Hsu HC, Fletcher JA, (1999) Investigation of chromosomal aberrations in hepatocellular carcinoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 111: 21-27.
17. Yeh SH, Lin MW, Lu SF, Wu DC, Tsai SF, et al. (2004) Allelic loss of chromosome 4q21 approximately 23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. Hepatology 40: 847-854.
18. Huang GL, Li BK, Zhang MY, Zhang HZ, Wei RR, et al. (2010) LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma. World J Gastroenterol 16: 2046-2054.
19. Wang HY, Luo M, Tereshchenko IV, Frikker DM, Cui X, et al. (2005) A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genome Res 15: 276-283.
20. Hu G, Wang HY, Greenawalt DM, Azaro MA, Luo M, et al. (2006) AccuTyping: new algorithms for automated analysis of data from high-throughput genotyping with oligonucleotide microarrays. Nucleic Acids Res 34: e116.
21. Liu W, He L, Ramirez J, Ratain MJ, (2009) Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. Clin Cancer Res 15: 7602-7607.
22. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286.
23. Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N (2002) Quantitative analysis of heparanase messenger RNA expression in hepatocellular carcinoma. J Surg Oncol 81: 148-154; disscusion 154.
24. Ikeguchi M, Hirooka Y, Kaibara N, (2003) Heparanase gene expression and its correlation with spontaneous apoptosis in hepatocytes of cirrhotic liver and carcinoma. Eur J Cancer 39: 86-90.
25. Ikeguchi M, Fukuda K, Yamaguchi K, Kondo A, Tsujitani S, et al. (2003) Quantitative analysis of heparanase gene expression in esophageal squamous cell carcinoma. Ann Surg Oncol 10: 297-304.
26. El-Assal ON, Yamanoi A, Ono T, Kohno H, Nagasue N, (2001) The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7: 1299-1305.
27. Xiao Y, Kleeff J, Shi X, Buchler MW, Friess H, (2003) Heparanase expression in hepatocellular carcinoma and the cirrhotic liver. Hepatol Res 26: 192-198.
28. Nasser NJ, Avivi A, Shafat I, Edovitsky E, Zcharia E, et al. (2009) Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis. Proc Natl Acad Sci U S A 106: 2253-2258.
29. Nasser NJ, Nevo E, Shafat I, Ilan N, Vlodavsky I, et al. (2005) Adaptive evolution of heparanase in hypoxia-tolerant Spalax: gene cloning and identification of a unique splice variant. Proc Natl Acad Sci U S A 102: 15161-15166.
30. McKenzie EA, (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151: 1-14.
31. Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z, (2006) Development of heparanase inhibitors for anti-cancer therapy. Curr Med Chem 13: 2101-2111.
32. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, et al. (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50: 958-968.
33. Lewis KD, Robinson WA, Millward MJ, Powell A, Price TJ, et al. (2008) A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest New Drugs 26: 89-94.
34. Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, et al. (2010) Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol 21: 1302-1307.
35. Zetser A, Bashenko Y, Miao HQ, Vlodavsky I, Ilan N, (2003) Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63: 7733-7741.
36. Nobuhisa T, Naomoto Y, Okawa T, Takaoka M, Gunduz M, et al. (2007) Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci 98: 535-540.